Connect for Life

Partnership objectives

Enable local health professionals in resource-limited settings to improve diagnosis and treatment of those living with HIV and tuberculosis.

The program aims to improve diagnosis and treatment of those living with HIV and tuberculosis in limited-research settings. The program aims to improve diagnosis and treatment of those living with HIV and tuberculosis in limited-research settings. Copyright Johnson & Johnson Corporate Citizens Trust

Description of partnership activities and how they address needs and challenges

In collaboration with the Infectious Diseases Institute, the Ugandan Ministry of Health, and Johnson & Johnson Corporate Citizenship Trust, Janssen Pharmaceutical of Johnson & Johnson has launched the Ugandan Academy for Health Innovation and Impact as the flagship institute of Connect for Life™. This program deploys mobile and digital technologies, demonstration projects, and academies of independent local experts to help patients manage their disease, while also building capacity in local healthcare professionals to enhance detection, treatment and prevention of HIV and TB, and improve maternal and child health.

Partnership information

Company(ies) Johnson & Johnson

Partner(s) Uganda Infectious Diseases Institute, Uganda Ministry of Health

Type of Partner(s) Academia / Hospitals, Government

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS, Tuberculosis

Program Type(s) Health System Infrastructure - mHealth, Health System Infrastructure - Outreach & Medical Services, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) General population, Health professionals, Marginalised / Indigenous People, Patients in needs of treatment

Region(s) Sub-Saharan Africa

Number of Countries 48

Country(ies) Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe

Start Date 2016

More information Johnson & Johnson Press Release

Anticipated completion date Ongoing

« We hope this integrated, outcomes-based approach to tackling critical global health challenges at every stage of life will have long-term impact for whole communities in the world’s most vulnerable populations. »

Jaak Peeters, head of Global Public Health at Johnson & Johnson